



## ASX ANNOUNCEMENT

### Starpharma receives \$4.2M R&D tax incentive refund

**Melbourne, Australia; 29 October 2014:** Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has received the anticipated \$4.2M of R&D tax incentive refund relating to FY14 expenditures.

The R&D tax refund relates to Australian R&D expenditure and eligible overseas expenditure in Starpharma's VivaGel<sup>®</sup>, and DEP<sup>™</sup> docetaxel clinical programs.

Commenting on the refund, Starpharma CEO Dr Jackie Fairley said:

"The receipt of the R&D tax incentive further strengthens Starpharma's balance sheet following the recent financing.

"The R&D tax incentive program greatly assists Australian companies engaged in innovation by providing greater certainty of funding as they create the products of the future.

"Starpharma's VivaGel<sup>®</sup> condom, available to Australian consumers from today is a good example of a globally significant Australian innovation which has been developed and commercialised with the assistance of this important scheme."

#### ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development programs: VivaGel<sup>®</sup> portfolio, drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead products are based on VivaGel<sup>®</sup> (SPL7013, astodrimer sodium), a proprietary dendrimer which is a potent microbicidal agent. VivaGel<sup>®</sup> formulated as a water based gel and delivered vaginally is under clinical development for the management and prevention of bacterial vaginosis (BV). Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries, Inc., (TSE: JP3192800005) to market a value-added, VivaGel<sup>®</sup> condom. Okamoto is the market leader for condoms sold in Japan, which is the world's second largest condom market. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles<sup>®</sup>, ZERO<sup>®</sup> and SKYN<sup>®</sup>.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Drug Delivery partners include GSK, Lilly and AstraZeneca. A number of dendrimer-enhanced, or DEP<sup>™</sup> versions of existing drugs are under development. The most advanced of these is DEP<sup>™</sup> docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere<sup>®</sup>), which is in clinical development. In preclinical studies DEP<sup>™</sup> docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere<sup>®</sup> (docetaxel).

In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

#### FOR FURTHER INFORMATION

##### **Media:**

##### **Buchan Consulting**

Rebecca Wilson

Mob: +61 417 382 391

[rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

Gabriella Hold

+61 3 9866 4722

[ghold@buchanwe.com.au](mailto:ghold@buchanwe.com.au)

##### **Starpharma:**

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary

+61 3 8532 2704

[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)

[www.starpharma.com](http://www.starpharma.com)

##### **Forward Looking Statements**

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.